NCT07227402 2026-04-17
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
12 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT01575548 2026-04-13
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03055013 2026-04-13
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03793166 2026-04-13
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06661720 2026-04-07
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05863351 2026-04-03
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03815643 2026-03-31
Avelumab Program Rollover Study
EMD Serono
Phase 3 Active not recruiting
NCT07489495 2026-03-24
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting